Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 4:36 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 338 matching trials from the live ClinicalTrials.gov search.
Conditions
Advanced Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma, Metastatic Pancreatic Adenocarcinoma, Metastatic Triple-Negative Breast Carcinoma, Pancreatic Ductal Adenocarcinoma, Stage III Breast Cancer AJCC v7, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage III Lung Small Cell Carcinoma AJCC v7, Stage III Pancreatic Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Small Cell Carcinoma AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Small Cell Carcinoma AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Small Cell Carcinoma AJCC v7, Stage IV Pancreatic Cancer AJCC v6 and v7, Triple-Negative Breast Carcinoma, Unresectable Lung Small Cell Carcinoma, Unresectable Pancreatic Adenocarcinoma, Unresectable Pancreatic Carcinoma, Unresectable Triple-Negative Breast Carcinoma
Interventions
18F-Fluoromisonidazole, Cediranib Maleate, Laboratory Biomarker Analysis, Olaparib, Positron Emission Tomography
Other · Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
14
States / cities
La Jolla, California • Sacramento, California • San Diego, California + 9 more
Conditions
brca1 Mutation Carrier, brca2 Mutation Carrier, Breast Cancer
Interventions
cholecalciferol, placebo
Dietary Supplement · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 50 Years · Female only
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
360
States / cities
Anniston, Alabama • Mobile, Alabama • Anchorage, Alaska + 230 more
Conditions
Breast Cancer
Interventions
high performance liquid chromatography, laboratory biomarker analysis, mass spectrometry, medical chart review
Other
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
2
States / cities
Rochester, Minnesota • Omaha, Nebraska
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Breast Cancer, Breast Cancer Female, DCIS, Stage II Breast Cancer, Stage I Breast Cancer
Interventions
Partial Chest Wall Radiation Therapy
Radiation
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
Stony Brook, New York
Conditions
Benign Breast Neoplasm, Ductal Breast Carcinoma In Situ, Invasive Breast Carcinoma, Lobular Breast Carcinoma In Situ, Paget Disease of the Breast, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
Docosahexaenoic Acid, Placebo
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
4
States / cities
Boston, Massachusetts • New York, New York • Houston, Texas
Conditions
Breast Cancer
Interventions
gene expression analysis, mutation analysis, proteomic profiling, reverse transcriptase-polymerase chain reaction, fluorescent antibody technique, immunohistochemistry staining method, laboratory biomarker analysis, liquid chromatography, mass spectrometry, medical chart review, quality-of-life assessment
Genetic · Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
20 Years and older · Female only
Enrollment
563 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2019
U.S. locations
3
States / cities
Beverly Hills, California • Duarte, California • Pasadena, California
Conditions
Ductal Breast Carcinoma In Situ, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer
Interventions
Contrast-enhanced Magnetic Resonance Imaging, Mammography, Therapeutic Conventional Surgery, Ultrasonography, Gadolinium
Procedure · Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Conditions
DCIS
Interventions
Decision Board
Device
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
25 Years and older · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
Ductal Carcinoma in Situ
Interventions
lapatinib
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Ductal Breast Carcinoma In Situ, Estrogen Receptor Positive
Interventions
Afimoxifene, Laboratory Biomarker Analysis, Placebo, Tamoxifen Citrate
Drug · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
6
States / cities
Chicago, Illinois • Edgewood, Kentucky • Rochester, Minnesota + 3 more
Conditions
Central Nervous System Metastases, Invasive Ductal Breast Carcinoma, Invasive Ductal Breast Carcinoma With Predominant Intraductal Component, Invasive Lobular Breast Carcinoma, Invasive Lobular Breast Carcinoma With Predominant in Situ Component, Liver Metastases, Lobular Breast Carcinoma in Situ, Lung Metastases, Male Breast Cancer, Medullary Ductal Breast Carcinoma With Lymphocytic Infiltrate, Mucinous Ductal Breast Carcinoma, Papillary Ductal Breast Carcinoma, Recurrent Breast Cancer, Stage IV Breast Cancer, Tubular Ductal Breast Carcinoma, Tumors Metastatic to Brain
Interventions
hyperfractionated radiation therapy, laboratory biomarker analysis, stereotactic radiosurgery
Radiation · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2024
U.S. locations
1
States / cities
North Chicago, Illinois
Conditions
Breast Cancer, Carcinoma, Ductal
Interventions
Intra-Operative Radiotherapy (IORT), Lumpectomy, Whole Breast Radiotherapy, Intracavitary Brachytherapy, Accelerated External Beam 3-D Conformal Radiotherapy, Stereotactic APBI
Radiation · Procedure
Lead sponsor
Stanford University
Other
Eligibility
40 Years and older · Female only
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2029
U.S. locations
1
States / cities
Stanford, California
Conditions
Breast Cancer, Colorectal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastric Cancer, Head and Neck Cancer, Liver Cancer, Lung Cancer, Metastatic Cancer, Ovarian Cancer, Pancreatic Cancer, Testicular Germ Cell Tumor
Interventions
CEA RNA-pulsed DC cancer vaccine
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Breast Cancer
Interventions
Accuboost APBI
Device
Lead sponsor
Brown University
Other
Eligibility
50 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
3
States / cities
La Jolla, California • Lakeland, Florida • Providence, Rhode Island
Completed Not applicable Interventional Accepts healthy volunteers Results available

Spect Analysis of Cardiac Perfusion Changes After Whole Breast/Chest Wall Radiation Therapy With ABC

NCT00321048
Conditions
Breast Neoplasms, Carcinoma, Ductal, Adenocarcinoma
Interventions
Active Breathing Coordinator
Device
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Invasive Breast Cancer Early Stages, Ductal Carcinoma In Situ, DCIS
Interventions
VENUS SHELL™ immobilization device
Device
Lead sponsor
HeroSupport SA
Industry
Eligibility
40 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Conditions
Ductal Carcinoma In Situ, Invasive Breast Cancer
Interventions
Not listed
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
30 Years and older · Female only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Lebanon, New Hampshire
Conditions
Ductal Breast Carcinoma In Situ, Estrogen Receptor Positive, Invasive Breast Carcinoma, Progesterone Receptor Positive, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer
Interventions
Accelerated Partial Breast Irradiation, High-Dose Rate Brachytherapy, Questionnaire Administration
Radiation · Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
45 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
10
States / cities
Gilbert, Arizona • La Jolla, California • Royal Oak, Michigan + 6 more
Conditions
Breast Cancer
Interventions
3-dimensional conformal accelerated partial breast irradiation, brachytherapy, whole breast irradiation, MammoSite or other single-entry intracavitary device
Radiation
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older · Female only
Enrollment
4,216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2018
U.S. locations
374
States / cities
Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 295 more
Conditions
DCIS, Breast Cancer, Breast Neoplasms, Sentinel Lymph Node
Interventions
Delayed SLND, Late SLND
Diagnostic Test
Lead sponsor
Uppsala University
Other
Eligibility
18 Years and older · Female only
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Houston, Texas
Conditions
Breast Cancer
Interventions
IMRT/VMAT-Based Accelerated Partial Breast Irradiation
Radiation
Lead sponsor
Sanford Health
Other
Eligibility
50 Years and older · Female only
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Worthington, Minnesota • Sioux Falls, South Dakota
Conditions
Breast Cancer
Interventions
vorinostat, protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, neoadjuvant therapy, therapeutic conventional surgery
Drug · Genetic · Other + 1 more
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
San Francisco, California
Conditions
Mesothelioma, Glioblastoma, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Melanoma, Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Squamous Cell Carcinoma of Head and Neck, Cholangiocarcinoma, Breast Cancer, Ovarian Cancer, Cervical Cancer, Endocervical Cancer, Colorectal Cancer, Esophageal Cancer
Interventions
NGM707, NGM707 plus pembrolizumab (KEYTRUDA®)
Drug
Lead sponsor
NGM Biopharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
20
States / cities
Los Angeles, California • Newport Beach, California • Santa Monica, California + 15 more